The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...
One year after reports of supply chain issues, 49% of reports in the US and 34% of reports in Canada were associated with ...
Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.
Review shows lower odds of symptomatic UTI episodes in children with history of recurrent UTIs with nitrofurantoin, cranberry ...
Early-life exposure to nitrogen dioxide, fine particulate matter linked to prevalence and persistence of peanut allergy ...
Board Chairman Kelly Aberasturi told the AP that while he’s skeptical of COVID vaccines, he was supportive of but “disappointed” in the board’s decision.
The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for donidalorsen for the prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients aged ...
Increase in Parkinson disease risk seen in association with exposure to two or more courses of antifungals 1 to 5 years prior. HealthDay News — Adults who have received multiple penicillin courses ...
The FDA is expected to decide on treatments for familial chylomicronemia syndrome, type 1 diabetes, short bowel syndrome, and Prader-Willi syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback